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Abstract  
Breast cancer is the most frequent malignant neoplasia in women worldwide, with an estimated 
1.7 million cases and 521,900 deaths in 2012, accounting for 25% of all cancer cases and 15% of all 
cancer deaths among females. In western countries, incidence rates have been declining, however, in 
Portugal breast cancer age-adjusted incidence rates have been increasing for years. Indeed, breast 
carcinoma is the leading cause of cancer mortality among Portuguese women, with an estimated 6088 
new cases and 1570 deaths in 2012.  
Cancer is a complex group of diseases in which several cellular and molecular components of 
the tumor microenvironment contribute to the survival of cancer cells. The non-neoplastic cells of the 
tumor microenvironment including fibroblasts, adipocytes, immune and endothelial cells are 
determinant in cancer biology since they act as a functional network in which soluble factors and organic 
molecules are transiently shared. To fulfill the biosynthetic demands associated with proliferation, a cell 
must increase the import of nutrients that sustain survival and fuel cell growth, supported by a metabolic 
remodeling. In a proliferative tumor niche, fatty acids (FA) are crucial since they are both fuel and 
construction blocks, maintaining cell renewal and division.  
Conceptually, adipocytes are the main suppliers of FA, however our team published that cancer 
associated fibroblasts (CAFs) also function as hubs of FA to supply the needs of cancer cells. Breast 
cancer cells exposed to CAFs-conditioned media increased their lipid uptake and the expression of 
FATP1/SLC27A1 (FA transport protein 1), promoting FA transfer. FATP1 is an integral membrane 
protein known to enhance the uptake of long-chain and very long-chain FA into cells. Considering FA 
transfer from CAFs to breast cancer cells, FATP1 appears to be a suitable candidate to treat breast cancer 
and a possible marker of disease outcome.  
The present thesis aims to prove the role of FATP1 in breast cancer cells survival and behavior 
in order to validate its use as a therapeutic target. The main objective was divided in 3 specific aims: 
The first aim is to confirm that estrogen and FA regulate the expression of FATP1/SLC27A1, which is 
crucial for breast cancer cells. The second aim emerged from the evaluation of the results obtained in 
the first aim, and it is to evaluate the role of ER-b in FATP1/SLC27A1 regulation. The third aim is to 
target FATP1 with arylpiperazines, which were characterized as effective inhibitors of FATP1, testing 
a putative therapeutic approach.  
RQ-PCR and western blotting analysis showed that FA (linoleic acid (C18:2)) and estradiol 
stimulated FATP1/SLC27A1 expression, especially in MDA-MB-231, which has higher basal levels of 
FATP1/SLC27A1 mRNA in comparison with MCF7. Interestingly, we found that estradiol stimulated 
the binding of ER-b to the FATP1/SLC27A1 promoter. These findings prompted us to investigate the 
role of ER-b in FATP1/SLC27A1 regulation using an ER-b agonist, ERB-041 and an ER-b antagonist, 
PHTPP. Results revealed that PHTPP affects cell viability, the uptake of FA and increases the levels of 
FATP1 in the cell membrane in both cell lines. Also indicating that, besides ER-a, ER-b is a pro-survival 
effector in breast cancer cells and it should be tested as a prognostic marker. Wound healing and cell 
cycle analysis showed that FA and estradiol induced cell migration and proliferation.  
Our in vitro findings were supported by patients’ data showing a higher expression of 
FATP1/SLC27A1 in more aggressive and invasive breast carcinomas. Furthermore, the inhibition of 
FATP1 with arylpiperazines interfered with the uptake of FA and cell proliferation, validating the 
importance of FATP1 as a putative therapeutic target in breast cancer. 
Our study paves the path in order to elect FATP1 a suitable marker for breast cancer prognosis 
and a putative therapeutic target to better treat breast cancer patients. 
 
Keywords: breast cancer, tumor microenvironment, cancer metabolism, fatty acids (FA), 
FATP1/SLC27A1, FATP1, metabolic fitness, ER-b, arylpiperazines. 
 iii 
Resumo  
A neoplasia maligna da mama é a neoplasia mais frequente nas mulheres a nível mundial com 
cerca de 1.7 milhões de casos e 521,900 mortes em 2012, representando 25% de todos os casos de cancro 
e 15% de todas as mortes por cancro entre mulheres. Os países mais desenvolvidos são os que 
apresentam as maiores taxas de incidência enquanto que a mortalidade relativa é maior nos países menos 
desenvolvidos. A redução do uso de terapia de reposição hormonal na pós-menopausa e a participação 
em programas de rastreio através de mamografias baixaram as taxas de incidência nos países ocidentais, 
no entanto, em Portugal, estas taxas têm vindo a aumentar nos últimos anos. Entre as mulheres 
portuguesas o carcinoma da mama é a neoplasia maligna mais comum e a principal causa de morte por 
cancro, com 6088 novos casos estimados e 1570 mortes em 2012. Este aumento pode estar também 
relacionado com alterações nos padrões reprodutivos, obesidade e inactividade física.  O cancro da 
mama é dividido em vários subtipos com características moleculares intrínsecas: luminal A, luminal B, 
sobre-expressão de HER2 e basal. Os tipos luminal A e B são caracterizados pela expressão de 
receptores hormonais, enquanto que os restantes subtipos são menos propensos a expressar o receptor 
de estrogénio (ER) ou de progesterona (PgR), sendo que o basal não expressa ER, PgR e HER2 (tumores 
triplo negativos). A heterogeneidade biológica bem como a plasticidade dinâmica do microambiente 
tumoral são importantes desafios no estudo e o tratamento do carcinoma da mama. Exemplo disso, é a 
importância de conhecer o status do RE e HER2, uma vez que constituem indicadores de prognóstico e 
alvos terapêuticos relevantes. A acção do estrogénio é mediada pela ligação a receptores de estrogénio 
(ER-α e/ou ER-β) que são expressos em vários tecidos. Actualmente, apenas o ER-α tem sido usado na 
clínica como marcador de prognóstico e alvo terapêutico devido à sua elevada expressão proteica em 
lesões mamárias malignas em comparação com o tecido normal. A administração de fármacos 
antagonistas de estrogénios, como o tamoxifen, é eficaz no tratamento de cancro da mama, no entanto, 
estes fármacos têm diversos efeitos secundários e após tratamentos prolongados os tumores podem 
tornar-se resistentes. 
A doença oncológica é considerada mundialmente como um problema de saúde pública e é a 
segunda maior causa de morte em termos globais. A acumulação de alterações genéticas e epigenéticas 
permite às células escaparem à rede de controlo que regula o equilíbrio homeostático entre a proliferação 
celular e morte celular, levando a uma proliferação anormal de células. Uma neoplasia é considerada 
maligna se as suas células tiverem adquirido independência mitogénica e a capacidade de invadir os 
tecidos adjacentes. Durante a carcinogénese, 6 propriedades celulares fundamentais são alteradas: 
aumento da sinalização proliferativa, elevado potencial replicativo, insensibilidade aos sinais de anti-
mitogénese, capacidade de invasão tecidular e metastização, angiogénese sustentada e resistência à 
apoptose. Estas capacidades biológicas adquiridas durante esta transformação gradual e complexa são 
as chamadas hallmarks do cancro que foram recentemente revisitadas, emergindo 2 novas hallmarks, a 
reprogramação do metabolismo energético e evasão ao controlo imunitário.  
Para além das células tumorais, as células não malignas do microambiente tumoral, incluindo 
fibroblastos, adipócitos, células imunes e endoteliais são determinantes na biologia do cancro visto que 
actuam como uma rede funcional na qual factores solúveis e moléculas orgânicas são continuamente 
partilhados. Para cumprir os requisitos biossintéticos associados à proliferação, uma célula deve 
aumentar a importação de nutrientes que suportam a sobrevivência e alimentam o crescimento celular 
ocorrendo uma remodelação metabólica. Num nicho tumoral proliferativo, os ácidos gordos são 
essenciais visto que podem ser usados simultaneamente como combustível e como blocos de construção 
de forma a manter a renovação e divisão celular.   
A desmoplasia é relativamente frequente em carcinoma da mama, apesar de não ser 
característica exclusiva, e consiste numa alteração estromal caracterizada pela presença de estroma 
fibrótico que tem como principal componente celular os fibroblastos. Para além das células tumorais, 
os fibroblastos associados a cancro (CAFS) são a componente principal do microambiente tumoral e 
pensa-se que eles desempenhem um papel determinante no início e na progressão da doença. 
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Conceptualmente, os adipócitos são os principais fornecedores de ácidos gordos, no entanto, o nosso 
grupo de investigação demonstrou, em modelos in vitro e in vivo, que os CAFs cooperam com células 
de cancro da mama ao produzirem e fornecerem ácidos gordos a estas. As células de carcinoma da mama 
expostas a meio condicionado por CAFs aumentavam a absorção de lípidos bem como a expressão de 
FATP1/SLC27A1 (FA transport protein 1), promovendo a transferência de ácidos gordos. FATP1 é uma 
proteína membranar responsável pela absorção de ácidos gordos de cadeia longa e muito longa. A 
regulação da síntese, absorção e degradação de ácidos gordos é essencial para sustentar a fisiologia 
celular. Assim, limitar a disponibilidade de ácidos gordos às células tumorais de forma a perturbar o 
crescimento tumoral é uma possível abordagem terapêutica que poderá usar o FATP1 como alvo. 
Considerando a transferência de ácidos gordos dos CAFs às células de carcinoma da mama, o FATP1 
parece ser um candidato adequado para tratar o cancro da mama e um possível marcador de prognóstico. 
Em 2013, foram desenvolvidos uns fármacos que foram caracterizados como inibidores eficazes do 
FATP1, as arilpiperazidinas.  
Este projecto tem como objectivo demonstrar o papel do FATP1 na sobrevivência e 
comportamento das células de cancro da mama, de forma a validar o seu uso como factor de prognóstico 
e alvo terapêutico. Para atingir este objectivo foram delineados 3 objectivos específicos: o primeiro é 
confirmar que o estrogénio e os ácidos gordos regulam a expressão de FATP1/SLC27A1 e que esta 
proteína é crucial para as células de carcinoma da mama; o segundo objectivo surgiu aquando da análise 
dos resultados obtidos no primeiro objectivo e consiste em esclarecer o papel do ERb na regulação de 
FATP1/SLC27A1, e o terceiro objectivo é testar a inibição de FATP1 recorrendo à exposição a 
arilpiperazidinas 5k e 12a na tentativa de delinear uma possível estratégia terapêutica.  
Os resultados de RQ-PCR e western blotting mostraram que os ácidos gordos (ácido linoleico 
(C18:2)) e estradiol estimulam a expressão de FATP1/SLC27A1, especialmente nas MDA-MB-231 que 
possui níveis basais mais elevados de mRNA FATP1/SLC27A1 em comparação com MCF7. 
Curiosamente, observámos que o estradiol estimula a ligação do ER-b ao promotor do 
FATP1/SLC27A1. Isto levou-nos a investigar o papel do ER-b na regulação do FATP1/SLC27A1 
utilizando um agonista do ER-b, o ERB-041 e um antagonista do ER-b, o PHTPP. Os resultados 
revelaram que o PHTPP afecta a viabilidade celular, a absorção de ácidos gordos e aumenta os níveis 
de FATP1 na membrana celular em ambas as linhas celular indicando que para além do ER-a, o ER-b 
actua como um factor de pro-sobrevivência em células de carcinoma da mama e deveria ser investigado 
como eventual marcador de prognóstico. Observámos igualmente que os ácidos gordos e o estradiol 
induzem a migração e a proliferação celular. Os resultados in vitro estão de acordo com dados de doentes 
que mostram uma maior expressão de FATP1/SLC27A1 em carcinomas da mama mais agressivos e 
invasivos. Por conseguinte, a inibição do FATP1 com as arilpiperazidinas interferiu com a absorção de 
ácidos gordos e com a proliferação celular validando a importância do FATP1 como um potencial alvo 
terapêutico em cancro da mama.  
O nosso estudo inicia um percurso de investigação que acreditamos que permitirá eleger o 
FATP1 como um marcador de mau prognóstico do cancro da mama e um potencial alvo terapêutico. 
 
Palavras chave: cancro da mama, microambiente tumoral, metabolismo tumoral, ácidos gordos, 
FATP1/SLC27A1, FATP1, adaptação metabólica, ER-b, arilpiperazidinas. 
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1. Introduction  
1.1 Cancer Biology 
 
Cancer is a major public health problem worldwide and is the second leading cause of death 
globally 1. The accumulation of genetic and epigenetic changes allows cells to escape the network of 
controls that regulate the homeostatic balance between cell proliferation and cell death, leading 
ultimately to an abnormal division of cells 2. A tumor is considered cancer only if it is malignant, that 
is, only if its cells have acquired the ability of dividing relentlessly and invade surrounding tissues 3. 
These features of malignancy drive cancer cells to break loose, enter blood or lymphatic vessels and 
form secondary tumors, called metastases, at other sites in the body.   
During carcinogenesis, six fundamental cellular properties are altered: sustaining proliferative 
signaling, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless replicative 
potential, sustained angiogenesis and cell death resistance 2. These biological capabilities acquired 
during this multistep transformation are the so-called hallmarks of cancer that were recently revisited, 
emerging two new hallmarks, reprogramming of energy metabolism and evading immune destruction 4. 
Beside cancer cells, the non-neoplastic cells of the tumor microenvironment including stromal and 
endothelial cells are determinant in cancer biology since they act as a functional network in which 
soluble factors and organic molecules are transiently shared 5. 
 
1.2 Breast cancer 
 
Breast cancer is the most frequent malignant neoplasia in women worldwide, with an estimated 
1.7 million cases and 521,900 deaths in 2012, accounting for 25% of all cancer cases and 15% of all 
cancer deaths among females 6. The same authors described that breast cancer in more developed 
countries represents one-half of all breast cancer cases and 38% of deaths. Northern America, Northern 
and Western Europe countries have higher incidence rates, while relative mortality is greatest in less 
developed countries 6,7,8. Breast incidence rates vary internationally as a result of the differences in the 
availability of early detection as well as risk factors including reproductive and hormonal factors 9,10. 
Reductions in the use of postmenopausal hormone replacement therapy and plateaus in participation of 
mammography screening led to declining incidence rates in western countries 11–13, however, in Portugal 
breast cancer age-adjusted incidence rates have been increasing for years (ROR-Sul, 2015). Indeed, 
breast cancer is the most common cancer and the leading cause of cancer mortality among Portuguese 
women, with an estimated 6088 new cases and 1570 deaths in 2012 14. This increasing trend might be 
explained by changing reproductive patterns, obesity and physical inactivity 10.  
Additionally, although therapeutic approaches such as surgery, chemotherapy, radiation and 
endocrine therapy have reduced mortality rates, there are still many therapeutic failures resulting in 
cancer recurrence, metastasis and death. Metastatic breast carcinoma remains an incurable disease by 
current treatment strategies, accounting for 90% of breast cancer mortality 15. More recently, the 
potential harms of screening mammography have been discussed and it has been shown that this method 
may cause false-positive results, overdiagnosis and overtreatment of some breast carcinomas  6,16,17. In 
fact, women with large breasts may be at higher risk of radiation-induced breast cancer, however, the 
benefits of mammography outweigh these risks 18.  
Breast cancer is not a single disease process but rather a compilation of several and unique 
subtypes as defined via gene expression analysis 19. Microarray techniques have divided breast cancer 
into various intrinsic subtypes: luminal A, luminal B, HER2-enriched and basal. Luminal A and B are 
characterized by the expression of hormone receptor-related genes while both HER2-enriched and basal 
subtypes are less likely to express Estrogen Receptor (ER) or Progesterone Receptor (PgR). Regarding 
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prognosis, tumors of the ER positive luminal subtype have been shown to exhibit a better outcome as 
well as higher relapse-free and overall survival time comparing with those of the ER negative basal 
subtype 20. The morphological heterogeneity of breast carcinoma constitutes the basis for the 
histopathological classification of breast cancer. The WHO (world health organization) currently 
recognizes the existence of at least 18 distinct histological types of invasive breast cancer, however the 
large majority (50-80%) are invasive ductal carcinomas (IDC) 21. The biological diversification of breast 
cancer phenotypes accompanied by dynamic plasticity of the tumor microenvironment make tumor 
categorization an imperative task since it relates to therapeutic responses and disease progression 22. 
 
1.2.1 Estrogen receptors in breast cancer 
 
Besides being essential for normal growth and differentiation in the mammary gland, estrogens 
play a major role in promoting the proliferation of neoplastic breast epithelium 23. High levels of serum 
estrogen correlate with an increased risk of breast cancer 24. Estrogen action is mediated by binding to 
estrogen receptors (ER-α and/or ER-β) which are expressed in a number of tissues, forming functional 
homodimers or heterodimers. ER-α and ER-β are encoded by distinct genes located on different 
chromossomes, respectively, chromosome 6 (ESR1) and chromosome 14 (ESR2),  and act as 
transcription factors after estrogen binding 25.  
The classical pathway of estrogen action states that in the absence of estrogen, ER binds to Heat-
Shock Proteins (HSP 50, 70 and 90), however, when estrogen is present, the HSPs are liberated from 
the ligand-receptor complex, inducing a conformational change in the receptor and promoting 
dimerization. ER, as a homodimer, subsequently binds to estrogen receptor elements (EREs) in the 
regulatory regions of target genes to either activate or repress gene expression 26.  
Presently, only ER-α has been used in a clinical setting, since its protein levels are elevated in 
malignant breast lesions compared with normal tissue, allowing its use as a predictive, prognostic 
marker and a therapeutic target. Administration of estrogens antagonists, such as tamoxifen, is 
effectively useful in the treatment of breast cancer 27. However, these drugs have unwanted side effects 
in non-target tissues and after prolonged treatment, tumors become resistant 28. Only few studies have 
investigated the potential prognostic role for ER-b in breast cancer until now. Speirs et al., found ER-β 
mRNA as being significantly upregulated in tamoxifen-resistant breast cancers compared with 
tamoxifen-sensitive tumors, suggesting a link between ER-b overexpression and tamoxifen resistance. 
On the other hand, further studies reported that high expression of ER-b protein was associated with a 
good outcome in breast cancer patients treated with tamoxifen 30. Accordingly, ER-b prognostic and 
predictive value remains controversial, however, targeting this receptor in some cases could offer new 
treatment options for breast cancer patients where previously only aggressive chemotherapies were 
available 31.  
1.3 Cancer metabolism 
 
Although cancer metabolism is one of the oldest areas of research in cancer biology, the study 
of metabolic alterations in tumors has grown exponentially over the past decade 32,33. To fulfill the 
biosynthetic demands associated with proliferation, a cell must increase the import of nutrients such as 
glucose and glutamine that support survival and fuel cell growth 34.  
The link between cancer and metabolism was first made by Otto Warburg in 1923 with the 
observation that most cancer cells predominantly produce energy through a high rate of glycolysis 
followed by acid lactic fermentation, rather than through oxidative phosphorylation (OxPhos) in the 
mitochondria 35. Thus, tumors exhibit an increased rate of glucose uptake with lactate production, even 
in the presence of oxygen, through aerobic glycolysis with the production of carbon skeletons, NADPH 
and ATP 36. Warburg thought cells would prefer fermentation as a source of energy instead of the more 
 3 
efficient OXPHOS- the Warburg Effect.  However, this view was challenged as several studies found 
that defects of mitochondrial OXPHOS are not common in spontaneous tumors and the function of 
mitochondrial OXPHOS in most cancers is intact 37–39.  
One of the most frequently altered pathways in cancer is the PI3K-Akt-mTOR signaling 
pathway that contributes to the uptake and utilization of several nutrients including glucose, glutamine, 
nucleotides and lipids 34, some of them are used in OXPHOS instead of glucose in highly glycolytic 
cells. Monocarboxylate transporters (MCTs) and lactate dehydrogenases (LDH) allow the production 
and export of lactate after glycolysis and subsequently the import and its conversion into pyruvate to 
supply tricarboxylic acid (TCA) cycle and OXPHOS for energy and biomass production 40–43. 
Glutamine, an important metabolic substrate and energy source for tumor cells, is converted to glutamate 
and channeled into the TCA Cycle as a-ketoglutarate, accounting for ATP and carbon skeleton 
production, essential for amino-acid, nucleotide and lipid biosynthesis 44. Glutamine can be converted 
to citrate, by the reversal of the Krebs cycle reactions, which in turn can be used for the production of 
acetyl-groups for fatty acids (FA) synthesis 45,46,47. An increased rate of lipid synthesis in malignant 
tissues has also been recognized as an important aspect of the rewired metabolism of transformed cells48. 
 
1.3.1  Fatty acids (FA) metabolism and cancer 
 
Synthesis of fatty acids (FA) is a fundamental cellular process, which converts nutrients into 
metabolic intermediates for membranes biosynthesis, energy storage and the production of signaling 
molecules 49. Being cellular proliferation the main characteristic of all cancers, FA are crucial in the 
microenvironment since they can be used as fuel and construction blocks, maintaining cell renewal and 
division 50,51. FA are composed by a terminal carboxyl group and a hydrocarbon chain, occurring 
frequently in even numbers of carbons which can be saturated or unsaturated 45.  
While most normal human cells prefer exogenous sources, tumors generate almost all their 
cellular FA through de novo synthesis 52. The metabolic intermediate that provides the substrate for the 
synthesis of FA is cytoplasmic acetyl-CoA that can be produced through different ways. Glucose or 
glutamine generates citrate that is cleaved by ATP-citrate lyase (ALCY) to oxaloacetate and acetyl-
CoA, here ALCY is phosphorylated and activated by AKT 53,54. Then, acetyl-CoA is carboxylated to 
malonyl-CoA and condensed by FA synthase (FASN), attaching them to acyl carrier protein (ACP) to 
generate subsequentially palmitate. Palmitate is a 16-carbon saturated FA (16:0) that is elongated to 
produce other molecules of various lengths. Together with the uptake of essential FA from the 
environment, they form a pool of intracellular FA that can be used for the generation of triacylglycerols 
(TGs) for energy storage, glycerophospholipids and sphingolipids for membrane synthesis and 
eicosanoids for signaling processes 49. FA are sequentially degraded to acetyl-CoA, which can 
subsequently be oxidized by the TCA cycle to produce ATP in a process called mitochondrial b-
oxidation. In this process, NADH and FADH2  are used by the electron transport chain to generate ATP 
for many cellular mechanisms 55.  
 
 
1.3.2  Fatty acids (FA) synthesis 
 
The regulation of the synthesis, uptake and degradation of FA is essential for sustaining cellular 
physiology and perturbation of the processes controlling lipid provision can impair cell survival. 
Limiting FA availability to cancer cells in order to disturb tumor growth is therefore a potential 
therapeutic target in cancer. Studies have proposed the inhibition of FASN as a strategy to treat cancer, 
being some inhibitors evaluated in preclinical trials 56–59. However, FASN inhibitors have several side 
effects 60 and FASN was shown to be essential for adult neuronal stem cell function, raising additional 
concerns 61. Another issue is the potential metabolic flexibility of cancer cells which could lead to 
adaptation and resistance, for example, cancer cells could switch from de novo FA synthesis to FA 
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uptake in the presence of FASN inhibitors 49. Hence, the design of new soluble drugs that can be applied 
systemically is needed. The role of FA transporters in the control of cellular FA uptake under normal 
conditions and their implication in metabolic alterations occurring in cancer suggest that the blockade 
of these transporters could also work as an attractive therapeutic approach.  
 
1.3.3  Fatty acids (FA) transporters  
 
In terms of FA transport, it is acknowledged that membrane-associated FA-binding proteins, 
known as FA transporters, facilitate the cellular entry of FA across the cell membrane instead of  passive 
diffusion 62. To date, four groups of FA transporters have been identified: Plasma Membrane FA Binding 
Protein (FABP) family, FA transport proteins (FATP), FA translocase/CD36 and Caveolin-1 63. 
Although these proteins are commonly referred as “FA transporter” little is known about their exact 
biological functions and mechanisms by which each one of these proteins participate in the transport 
process across the cell membrane 63–66. These proteins differ in molecular mass and degree of post-
translational modifications, some have characteristic patterns of tissue distribution and others are 
expressed ubiquitously 63. 
Given their important roles in FA transport, the FATP proteins have been considered as viable 
targets to prevent aberrant accumulation of fat in cells and tissues leading to lipotoxic disease 67. In 
particular, FATP1 was chosen as a therapeutic target for the treatment of insulin resistance and several 
arylpiperazines were selected as inhibitors by high throughput screening 68. 
 
1.4 Metabolic remodeling in breast cancer  
 
Metabolic reprogramming is one of the emerging hallmarks of cancer 4,5 and it is well 
acknowledged that cancer cells have a vast metabolic plasticity in order to support continuous cell 
growth and proliferation meeting their energetic and biomass demands 41. The metabolic adaptation of 
tumor cells not only allows the development and establishment of a tumor in a certain microenvironment 
but also influences the response to therapy 69. Metabolic remodeling in the tumor niche is not exclusive 
to cancer cells, since stromal and endothelial cells share the same microenvironment 69. 
Therefore, the microenvironment surrounding cancer cells cannot be ignored as normal cells 
contribute for this adaptive process by sharing soluble factors and organic molecules that support 
cellular viability and proliferation 55. Indeed, a tight metabolic synergy occurs between epithelial cancer 
cells and stromal fibroblasts in which the normal cells act as suppliers of energy sources and precursors 
for macromolecules synthesis 41,70. The microenvironment is composed of both cellular (fibroblasts, 
adipocytes, endothelial and immune cells) and non-cellular components (proteins, proteases, cytokines 
- the extracellular matrix (ECM)) which synergistically play a role in cancer progression 69,71. 
Desmoplasia, a tissue phenomenon characterized by the presence of a fibrotic rich stroma 
around a tumor has long been associated with a poor clinical outcome in patients with cancer 72. In 
desmoplastic tissues, an increased proliferation of fibroblasts takes place causing the deposition of 
fibrotic stroma surrounding neoplastic cells. Although this stromal alteration is not an exclusive 
characteristic of breast cancer, it is rather frequent 50,73.  
Thus, besides cancer cells, cancer associated fibroblasts (CAFS) are the predominant cellular 
component of the tumor microenvironment, being thought to promote cancer initiation, progression and 
therapeutic response 74. In comparison with normal fibroblasts within the microenvironment, the higher 
proliferative rate of CAFs is sustained by increased glycolysis, glutaminolysis, autophagy, ketogenesis 
and FA synthesis 41,50,75–78. 
In breast carcinoma, tumor cells induce the down-regulation of caveolin-1, a known breast 
cancer stromal biomarker, reprogramming normal fibroblasts to CAFs concomitant with 
autophagic/lysosomal degradation 72. Hence, CAFs are reprogrammed by cancer cells and tumor 
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microenvironment 69. In the tumor niche, to sustain the metabolic demands there is a glycolytic switch 
in CAFs induced by a decreased oxygen availability, Reactive Oxygen Species (ROS) disequilibrium, 
activity of growth factors (TGF-b, IL-6) and hypoxia inducible factor-1 alpha (HIF-1a) stabilization 79–
81. It has been shown that CAFs isolated from breast cancer patients with poor prognosis express high 
levels of glycolytic enzymes and that the increased glycolytic rate in CAFs results in an enriched lactate 
microenvironment being lactate further imported and catabolized by cancer cells 82,83.  Lactate which is 
converted to pyruvate provides a mechanism for tumor growth as these metabolites can enter into the 
TCA cycle in cancer cells which are using oxidative metabolism promoting efficient energy production 
and higher proliferative capacity 83. There is also the activation of GPER/cAMP/PKA/CREB and 
PI3K/AKT signaling pathways that fuel mitochondrial biogenesis and oxidative metabolism of cancer 
cells 41,83,84. 
Autophagy is a survival mechanism in which cells degrade and recycle their own structural 
components to obtain sufficient energy to stay alive at critical times, however if it lasts too long cells 
will undergo cell death 85. Autophagy seems to play a key role in supporting CAFs phenotype as active 
suppliers of energy sources for cancer cells: autophagic CAFs favor the pro-tumorigenic nutrient-rich 
microenvironment and tumor cells, in nutrient detriment or energy restraint, can be fed by products 
resulting from autophagic CAFs 69,86,87. 
In breast cancer, adipocytes are an essential source of FA for cancer cells 88. Cancer Associated 
Adipocytes (CAAs) have an important role in the tumor microenvironment and exhibit phenotypical 
and biological changes that support cancer demands. CAAs secret adipokines such as leptin and Insulin 
Growth factor (IGF) that act on cancer cells activating tumor progression and metastasis 89,90. Other 
relevant intervenients are the tumor associated macrophages (TAMs) which are associated with tumor 
initiation, growth, invasion and metastasis. TAMs secrete Tumor Growth Factor B (TGFb) and 
Interleukin-10 (IL-10) that stimulate cancer cells to switch to a metastatic phenotype 91. Both CAAs and 
TAMs are responsible for the release of  Vascular Endothelial Growth Factor (VEGF) stimulating 
angiogenesis 41,92,93. Blood vessel supply is crucial for tumor survival not only by providing oxygen and 
nutrients for anabolism but also by removing waste products from cellular metabolism, contributing for 
the metabolic adaptation of the tumor 94. 
 
1.5 Metabolic crosstalk between breast cancer cells and CAFs mediated by FA Transporter 1 
(FATP1)  
 
Conceptually, the only hub of lipids within the tumor microenvironment is adipocytes. 
However, recently, our team 50 demonstrated that CAFs cooperate with breast cancer cells as FA 
producers and suppliers, in in vitro and in vivo models. Breast cancer cells exposed to CAFs-conditioned 
media increased their lipid uptake and the expression of FATP1, promoting FA transfer. These results 
disclose, for the first time, FATP1 as a putative target to suppress lipid symbiosis between CAFs and 
breast cancer cells, thereby disturbing tumor progression.  
FA transport proteins or solute carrier family 27 (SLC27) form a highly conserved family of six 
integral membrane proteins FATP1-6 95. FATPs enhance the uptake of long-chain and very long-chain 
FA into cells and are differentially expressed in a tissue-specific manner 63. FATP1 is expressed in 
different tissues such as brain, kidney, lung, skin, adipose tissue, heart and skeletal muscle. It is encoded 
by the SLC27A1 gene and has approximately 63 kDa. Interestingly, FATP1 is an insulin-sensitive 
transporter as it was reported that FATP1 translocates from an intracellular compartment to the plasma 
membrane in response to insulin, in adipocytes and skeletal myocytes 96. 
FA are thought to be transported by FATP1 across the membrane and activated by plasma 
membrane acyl-CoA synthetase (ACS1) to form acyl-Co esters. The rapid esterification of FA to CoA 
thioesters by ACS1 is a process known as vectorial acylation 97. FATPs function have been shown to be 
determinant in metabolic disease context, motivating the development of drugs to abrogate the transport 
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of FA across cell membranes 68,98. Drugs targeting ACS1 which is associated to FATP1 were developed 
but showed reduced efficacy 50,98. In a tumoral context, a possible role of FATPs in tumor metabolism 
has been described, demonstrating that FATP1/SLC27A1 mRNA expression was increased in rat 
hepatomas in comparison with normal liver tissue which correlated with FA uptake rates 55,99,100. FATP1 
expression is elevated in adipose tissue of obese patients, as well as in the heart, skeletal muscle and 
adipose tissue of mice models of obesity 55, consequently, it is possible that this protein might have a 
role in obesity-sensitive cancers. As mentioned before, FATP1 is an insulin-sensitive transporter which 
fundaments the use of anti-diabetic drugs in the treatment of breast cancer that is described in some 
studies. Epidemiological and clinical studies showed that metformin, a drug prescribed for type 2 
Mellitus diabetes, reduces the risk of cancer in patients with diabetes and improves prognosis and 
survival rate of cancer patients 101.  
 
1.6 Arylpiperazines as a therapeutic approach in breast cancer  
 
Considering FA transfer from CAFs to breast cancer cells, FATP1 appears to be a suitable 
candidate to treat breast cancer and a possible marker of disease outcome. In 2013, arylpiperazines were 
pointed out as effective inhibitors of FATP168. Through a derivatization process, arylpiperazines 
derivatives 5k and 12a were identified as maintaining potent chemical inhibitory effect against human 
and mouse FATP1 and also showed excellent pharmacokinetic properties. Although in this study 
arylpiperazines were tested for the treatment of insulin resistance, they could perfectly be applied in a 
breast cancer context. Moreover, these compounds are soluble and can be applied systemically which 
make them suitable to be used in cell culture. The destabilization of the metabolic crosstalk between 
CAFs and breast cancer cells, in order to inhibit tumor growth, could be achieved with these drugs.  
Therefore, the utilization of arylpiperazines in in vitro models of breast carcinoma might be a good 
strategy to test this innovative therapeutic approach in breast cancer. 
 
 
2. Hypothesis and aims of the project 
Our hypothesis is that FATP1 is crucial for breast cancer cells biology. To accomplish the main 
objective of this thesis, which is to prove the role of FATP1 in breast cancer cells survival and behavior 
in order to validate its use as a therapeutic target, this study was divided in three aims. The first aim is 
to confirm that estrogen and FA regulate the expression of FATP1/SLC27A1 and that this protein is 
crucial for breast cancer cells. The second aim emerged from the evaluation of the results obtained in 
the first aim, and it is to evaluate the role of ER-b in FATP1/SLC27A1 regulation. The third aim is to 
target FATP1 with arylpiperazines, testing a putative therapeutic approach.  
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3. Materials and methods  
3.1 Cell lines and culture conditions  
 
Human cell lines from triple-negative breast cancer, MDA-MB-231 (HTB-26™, ATCC) and 
from luminal-A breast cancer, MCF7 (HTB-22TM, ATCC) were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA). Cells were maintained at 37°C in a humidified environment 
of 5% CO2 in Dulbecco’s modified essential medium 1X (DMEM) (41965-039, Gibco, Life 
Technologies) containing 4.5g/L of D-glucose and 0.58 g/L L-glutamine. Medium was supplemented 
with 10% fetal bovine serum (FBS; S 0615, Merck), 1% Antibiotic-Antimycotic (AA; P06-07300, PAN 
Biotech) and 50 µg/mL Gentamicin (15750-060, Gibco, Life Technologies). Cells were cultured until 
an optical confluence of 75% - 100% before they were detached with 0.05% trypsin-EDTA 1X (25300-
054, Invitrogen). For in vitro assays, cell number was determined using a Bürker counting chamber. 
For gene expression analysis, mRNA was quantified by RT plus RQ-PCR (3.2) and protein 
quantification by western blotting (3.3) was performed. Cells (5x105 cells/well) were seeded in 6-well 
plates and synchronized under starvation (FBS free), for 8h. After starvation, cells were cultured in the 
presence and/or absence of FA (C18:2 - linoleic acid water-soluble, 96 µM; L5900, Sigma Aldrich; 
from now on called C18 in this thesis) and/or estradiol (1 nM; E4389, Sigma Aldrich) for 16h. To 
examine gene expression over time, a pulse chase assay was performed. Cells were seeded and cultured 
as described above and collected after 15 min, 30 min, 1h, 1h30min, 2h, 4h and 6h. 
 For wound healing assay (3.6), 2x105 cells/well were seeded in 12-well plates and cultured until 
reaching a confluent monolayer. Cell proliferation was inhibited with Mitomycin-C (5 μg/mL; M4287, 
Sigma), 3h prior the starting of the experiment. After, cells were exposed to FA and/or estradiol (as 
described above).  
 In cell death analysis (3.7), 1.5x105 cells/well were plated in 24-well plates. After starvation, 
cells were exposed to arylpiperazines (12a and 5k) in a range of concentrations from 0.125 to 125 μM, 
for 16h.  
For both cell cycle analysis (3.8) and lipid quantification/Nile red staining (3.9) by flow 
cytometry, 5x105 cells/well were plated in 6-well plates. After 8h of starvation, cells were exposed to 
FA and/or estradiol with and without arylpiperazines, 5k (0.125 μM and 12.5 μM) and 12a (12.5 μM 
and 125 μM), for 16h.  
For FATP1 levels quantification (3.5) by flow cytometry, 1.5x105 cells/well were plated in 24-
well plates and synchronized under starvation for 8h. After starvation, cells were exposed to estradiol 
(1 μM) and/or C18 (96 μM) and/or PHTTP (50 μM, ERb antagonist; SML1355, Sigma Aldrich) and/or 
ERB-041 (1 μM, ERb agonist; PZ0183, Sigma Aldrich), for 16h. 
 Additionally, cells were exposed to estradiol (1 μM) and/or C18 (96 μM) and/or PHTTP (50 
μM, ER-b antagonist) and/or ERB-041 (10 μM, ER-b agonist), for 16h and cell death and lipid 
quantification assays were performed as described above.  
In all in vitro assays, control cells were maintained in culture medium free of FA, estradiol, 
arylpiperazines, ERB-041 and PHTTP.  
 
3.2 RNA extraction, reverse transcription (RT) and relative quantifying real-time polymerase 
chain reaction (RQ-PCR) 
 
In the present thesis, the modulation of FATP1/SLC27A1, ESR1 and ESR2 genes expression by 
FA (C18) and/or estradiol was evaluated by RQ-PCR. Gene transcription can be evaluated by mRNA 
quantification in biological samples, using reverse transcription (RT). This technique is based in a 
single-stranded complementary DNA copy (cDNA) from a RNA template, through the action of the 
enzyme reverse transcriptase. Quantifying real-time polymerase chain reaction (qRT-PCR) measures 
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gene expression with accuracy and sensitivity, allowing both absolute (AQ-PCR) or relative (RQ-PCR) 
quantification of cDNA (Derveaux et al., 2010; Freeman et al., 1999). The RQ-PCR analysis is 
normalized for a housekeeping gene, which is constitutively expressed in cells  (Gubern et al., 2009).  
RNA was extracted using RNeasy Mini Kit Qiagen® (74104, Qiagen), according to the 
manufacturers’ protocol. RNA concentration in samples were measured at 260nm, in a NanoDrop 2000 
(ND-2000, Thermo Scientific). cDNA was synthesized from 1μg of total RNA by incubation at 70 °C 
for 10 min with random primers (11034731001, Roche) and with bidistilled water to complete a final 
volume of 8uL. Then, cDNA was reversely-transcribed using SuperScript™ II reverse transcriptase 
(18080-44, Invitrogen), RNAse OUT™ (10777-019, Invitrogen) and deoxynucleotides (dNTPs) mix 
(10mM; 28-4065-22V, 28-4065-02V, 28-4065-12V and 28-4065-32V, GE Healthcare), according to the 
manufacturers’ protocol.  
 RQ-PCR was performed using cDNA, specific pairs of primers for genes of interest 
(Supplementary Table 1) and SYBR® Green Master Mix (04707516001, Roche), according to 
manufacturer’s instructions, using a Lightcycler® 480 System instrument (05015243001, Roche). 
Hypoxanthine-guanine phosphoribosyltransferase 1 gene (HPRT1) was used as a housekeeping gene.  
 
3.3 Western blotting  
 
Western blotting is one of the gold standard technique used to evaluate protein levels, allowing 
the detection of antibody-targeted proteins in biological samples (Y. Liu et al., 2011). 
 Cell pellets were lysed in Radio-Immunoprecipitation Assay (RIPA) buffer (Appendix) and 
stored at -20ºC. Cell lysates were centrifuged at 11000 g (in a fixed angle rotor, Eppendorf, f45-30-11) 
for 4 min at 4ºC and supernatants were collected. Protein concentration was established by Bradford 
method, using Bio-Rad protein assay reagent (500-0006, Bio-Rad) through spectotrophometric 
quantification (595 nm). After protein quantification, loading buffer 5x (Appendix) with 10% β-
mercaptoethanol (M3148, Sigma) was added to each cell lysate and boiled at 95-100ºC for 10 min, to 
denature proteins. Then, samples were centrifuged at 11000 g for 2 min at 4ºC and placed on ice. 
 The same amount of total protein in each sample was loaded in 15% polyacrylamide gel (Tris-
glycine SDS-Polyacrylamide gel) (Appendix) and electrophoresis was carried out in MINI-PROTEAN 
Tetra Electrophoresis System (Bio-Rad) at 140V, into 1X TGS buffer (Tris-Glycine-SDS 10x (TGS); 
161-0772, Bio-Rad). After, proteins from the gel were transferred to an Immun-Blot® PVDF membrane 
with Trans-Blot® Turbo TM Blotting system, at 25 V, 2.5 A for 13 min. 
 To avoid non-specific antibody binding, membranes were blocked using 3% (w/v) BSA in 
phosphate buffered saline 1x (PBS) 0.1% (v/v) Tween 20, for 2 h at room temperature (RT), with gentle 
shaking.	For protein detection, membranes were incubated with primary specific antibodies (mouse anti-
human FATP1, MAB3304, R&D systems; rabbit anti-human ERa, ab75635, Abcam; rabbit anti-human 
ERb, ab196787, Abcam) at appropriate concentrations (1:1000 in 3% (w/v) BSA in PBS 0.1% (v/v) 
Tween 20 (Appendix), 1:200  and 1:500 in 5% (w/v) non-fat milk in PBS 0.1% (v/v) Tween 20 
(Appendix), respectively, at 4ºC, ON, with shaking. 
 After, to remove unbound primary antibody membranes were rinsed 3 times, for 5-10 min, with 
PBS 1x 0.1% (v/v) Tween 20, followed by an incubation for 2h at RT with secondary antibody IgG-
conjugated Horse raddish peroxidase (HRP; anti-mouse, 31430, Thermo Scientific; 1:5000 in 3% (w/v) 
BSA in PBS 0.1% (v/v) Tween 20). Membranes were rinsed 3 x, for 5 min with PBS 1x 0.1% (v/v) 
Tween 20 and immunoreactive bands were detected by using ECL western blotting substrate 
(SuperSignal® West Pico Chemiluminescent Substrate (34080, Thermo Scientific) in a ChemiDoc XRS 
System (Bio-Rad) with Image Lab software. To normalize the protein levels in samples, membranes 
were re-incubated using mouse anti-human β-actin (A5441, Sigma; 1:5000 in 3% (w/v) BSA in PBS1x 
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0.1% (v/v) Tween 20), at 4ºC, ON. Protein levels were detected as described above. Bands were 
quantified using Image J software (rsb.info.nih.gov/ij/). 
 
3.4 Chromatin immunoprecipitation (ChIP) 
 
Chromatin immunoprecipitation (ChIP) is used to investigate interactions between proteins and 
chromatin in a cell (Collas, 2010) In the context of the current thesis, this technique was employed to 
analyze putative interactions between ER-a and b transcription factors and Estrogen Responsive 
Elements (ERE) sequences in FATP1/SLC27A1 promoter. Those regions localize in 5’UTR 
(unstranslated reagion) of FATP1/SLC27A1 gene between nucleotides –179 to –406. To crosslink 
proteins and DNA cells were treated with 37% formaldehyde at a final concentration of 1% (v/v), 
followed by an incubation with 125mM glycine (pH 9). Subsequently, cells were scraped, centrifuged 
at 150 g for 2 min and ChIP lysis buffer (Appendix) was added.  Cell lysates were sonicated and the 
size of the chromatin fragments (expected size between 1000bp and 500bp) was evaluated by 
electrophoresis, in a 1.2% (w/v) agarose gel. ChIP assay was performed using OneDay ChIP kit (kch-
onedIP-060, Diagenode) according to the manufacturer’s protocol. The chromatin complexes were 
immunoprecipitated with 1μl (~1μg/mL) of specific antibodies: rabbit anti-human ERa (ab75635; 
Abcam) and rabbit anti-human ERb (ab196787; Abcam).  The relative occupancy of the 
immunoprecipitated factors at a specific promoter region was performed by RQ-PCR as described in 
section 3.3 and calculated using the following formula:  
 
Relative occupancy=2^(CtNegCtl − CtTarget) 
 
3.5 FATP1 levels by flow cytometry  
 
To evaluate the effects of estradiol, PHTPP and ERB-041, with and without FA in FATP1 
expression, FATP1 levels were quantified using flow cytometry. Briefly, 1.5x105 cells/mL were plated 
in 24-well plates. After starvation, cells were exposed to PHTPP and ERB-041 with or without estradiol 
and FA. Cells were detached with PBS-EDTA, centrifuged at 230 g for 5 min, at 4ºC and washed with 
PBS-BSA (0,1%). Cells were incubated with 100 μL of FATP1 (1:500 in PBS-BSA 0,5%) with and 
without 0.1% saponin (47036, Sigma Aldrich), for 1h, at 4ºC. After, PBS-BSA 0,1% was added and 
cells were centrifuged at 230 g for 5 min, at 4ºC, followed by an incubation of 30 min with anti-mouse 
FITC (1:1000 in in PBS-BSA 0,5%; A11059, Invitrogen), with and without 0.1% saponin. After, cells 
were washed, centrifuged and resuspended in 300 μL PBS-BSA 0,1%. Samples were analysed in 
FACScalibur (Becton Dickinson) and data analyzed with FlowJo 8.7 software. 
 
3.6 Wound healing assay 
 
Wound healing assay is a method used to measure directional cell migration in vitro, mimicking 
cell migration during wound healing in vivo(Liang et al., 2007). This assay was performed in order to 
identify a potential role of FA and estradiol on cancer cell migration. 
 In each cell monolayer, a scratch was made to the diameter of the well, and the wound closure 
was followed by acquiring phase-contrast images (x200 field) at the following time points: 0, 1, 3, 6, 9, 
12, 24 and 48 h. Images were analyzed and quantified using ImageJ software.  
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3.7 Cell death analysis by flow cytometry  
 
Apoptotic cells, among other typical features, are characterized by DNA fragmentation and loss 
of nuclear DNA (Riccardi and Nicoletti, 2006). In normal viable cells, phosphatidyl serine (PS) is 
located on the inner surface of the cell membrane, however, in apoptotic cells, PS is translocated to the 
outer leaflet of the plasma membrane exposing PS to the external environment. Labeled Annexin V 
allows the identification of apoptotic cells by binding to the exposed PS, and propidium iodide (PI), 
which is not permeant to live cells, binds to double stranded DNA by intercalating between base pairs, 
thus staining necrotic cells. 
 In the context of the present thesis, apoptosis assay was performed to analyze the effect of 
arylpiperazines in breast cancer cells. After experimental conditions, supernatants were collected and 
cells were harvested with trypsin, centrifuged at 150 g for 2 min. Cell pellets were stained with 0.5 μl 
fluorescein isothiocyanate (FITC)-Annexin V (640906, BioLegend) plus 2.5 μl PI (50μg/mL; P4170, 
Sigma-Aldrich) in annexin V binding buffer 1X (Appendix) and incubated at RT, in dark for 15 min. 
After incubation, samples were resuspended in 200 μl PBS 1x 0.1% (v/w) BSA (Appendix) and 
centrifuged at 150 g for 2 min. Cells were resuspended in 100 μl of annexin V binding buffer 1X and 
analyzed by flow cytometry (FACScalibur – Becton Dickinson). Sample data was analyzed using 
FlowJo 8.7 software (https://www.flowjo.com).  
 
3.8 Cell cycle analysis by flow cytometry  
 
The cell cycle are ordered events involving cell growth and cell division, resulting in two new 
daughter cells. It is divided in four sequential stages: Gap 1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis 
(M). In the G1 phase, metabolic changes prepare the cells for the synthesis of DNA which is then 
replicated in the S phase that is followed by the G2 phase, in which the cell prepares for division and 
ultimately divides in mitosis (M phase). In the quiescent phase, G0, cells are not dividing. The DNA 
content in the cells at the G0/G1, S and G2/M phases can be accurately quantified using DNA staining 
dyes such as PI 108. After exposure to FA, estradiol and FA plus estradiol, cells were harvested and fixed 
in 70% ethanol, at 4ºC. Then, cells were centrifuged at 150 g for 5 min and the cell pellet were incubated 
with 100 μL of PI solution (50μg/mL PI; 0.1mg/mL RNase A, 0.05% Triton X-100) for 40 min, at 37ºC. 
After the incubation, PBS 1X was added, cells were centrifuged at 230 g for 5 min at 4ºC and then 
resuspended in 200 μL of PBS-BSA 0.1% (v/w). Samples were analysed in FACScalibur (Becton 
Dickinson) and data was analyzed with FlowJo 8.7 software.  
 
3.9 Nile red staining by flow cytometry 
 
Nile red staining assay was performed to study the role of arylpiperazines in the uptake of FA 
by breast cancer cells. Neutral and polar lipids in cells were quantified using Nile red, a fluorescent dye. 
Nile red staining was performed based on (Lopes-Coelho et al., 2017). Briefly, cells were detached with 
trypsin, washed with PBS 1x and stained with Nile Red (1 mg/mL in PBS 1x) for 15 min, at RT. After, 
cells were centrifuged and PBS-BSA-0.1% (v/w) was added. Samples were analysed on FACSCalibur 
flow cytometer (Becton-Dickinson) and data was analyzed with FlowJo 8.7 software. 
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3.10 Bioinformatics analysis 
 
Data from Gene Expression Omnibus (GEO) was used to analyze the gene expression of FATP1 
in human samples. Kaplan-Meier curves of overall survival (OS) and recurrence-free survival (RFS) of 
breast cancer patients were obtained from http://kmplot.com/analysis/. 
   
3.11 Statistical analysis  
 
Statistical analysis was performed using GraphPad Prism 6.0 software (www.graphpad.com). 
Sample data were presented as the mean (normal distribution) or median (non-normal distribution) ± 
SD. All assays were performed in independent triplicates. Comparisons between data from each group 
were statistically analyzed by a two-tailed unpaired Student's t-test. Differences between experimental 
conditions were statistically significant at p<0.05.  
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4. Results 
4.1 Linoleic acid (C18) and estradiol stimulate FATP1 expression 
 
In order to evaluate the modulation of FATP1 by estradiol and FA (C18), MDA-MB-231 and 
MCF7 cells were exposed to C18 and estradiol, in separate and in combination, using as control cells 
cultured in medium without both C18 and estradiol and supplemented with 1% FBS. The expression of 
FATP1 was analyzed by a RQ-PCR assay (Figure 4.1) and by western blotting (Figure 4.2).  
FATP1/SLC27A1 mRNA levels were significantly increased after 30 minutes of exposure to 
C18+estradiol in MDA-MB-231 cells (Figure 4.1 A) and after 15 minutes of exposure to C18 in the 
MCF7 cell line (Figure 4.1 B), comparing to cells cultured in control conditions. In both cases, 
FATP1/SLC27A1 mRNA levels suffered a boost in expression in the first minutes of exposure but then 
decreased with time. In figure 4.1 C, control cells from both cell lines were compared to assess the basal 
mRNA levels of FATP1/SLC27A1 and different starvation times were tested. The results revealed a 
significant different expression of FATP1/SLC27A1 between cell lines, being higher in MDA-MB-231.  
 
 
 
Figure 4.1 - Relative gene expression of FATP1/SLC27A1 in MDA-MB-231 and MCF7 cells. (a,b) In a pulse chase assay, 
cells were cultured in medium and exposed to estradiol, C18 and C18+estradiol over 360 minutes. (a) MDA-MB-231 cells 
presented higher levels of FATP1/SLC27A1 mRNA expression in the C18+estradiol condition after 30 minutes of exposure. 
(b) C18 stimulated FATP1 expression in MCF7 cells at 15 minutes of exposure. (c) Cells were submitted to different starvation 
times (0h, 8h and 16h) and the basal levels of FATP1/SLC27A1 mRNA expression were analyzed.  FATP1 levels were 
significantly higher in MDA-MB-231 cells in all cases. HPRT gene was used as endogenous control. Expression levels were 
normalized to control condition. Data are mean ± error bars of triplicates. *p≤0.05 **p ≤0.01 ***p ≤0.001. 
Concerning FATP1 protein levels assessed by western blotting, the same dynamic was observed 
in MDA-MB-231. After 16h hours of exposure, FATP1 protein levels were visibly higher in the 
C18+estradiol condition in MDA-MB-231 (Figure 4.2 A) whereas in MCF7, no significant differences 
were observed (Figure 4.2 B). 
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Figure 4.2 - FATP1 protein levels assessed by Western blotting. Cells were cultured in control, estradiol, C18 and 
C18+estradiol conditions. Protein levels were normalized to b-actin and are relative to those obtained for cells cultured in 
control conditions. (a) MDA-MB-231 cells showed higher levels of FATP1 protein in the C18+estradiol condition; (b) while 
in MCF7 there were no major differences between conditions 
As estrogen is known to have an essential role in the development and progression of breast 
cancer and since our previous results showed that estradiol in combination with C18 modulates 
FATP1/SLC27A1 expression, we analyzed the expression of estrogen receptors genes 1 and 2 (ESR1 
and ESR2) by RQ-PCR (Figure 4.3) and western blotting (Figure 4.4). In MDA-MB-231, an ER- cell 
line, the expression of ESR1 was significantly higher when cells were exposed to estradiol, in 
comparison with the control condition in the first 30 minutes of exposure and then at 90 minutes. At 15 
minutes of exposure, C18+estradiol condition also showed increased levels of ESR1 (Figure 4.3 A). On 
the other hand, in MCF7, ER+ cell line, ESR1 mRNA levels did not increase with any of the stimulus 
(Figure 4.3 B). A statistically significant increase of ESR2 mRNA levels was observed with 
C18+estradiol exposure over time in MDA-MB-231 (Figure 4.3 C) whereas in MCF7 no differences 
between conditions were observed (Figure 4.3 D).  In terms of basal expression of ESR1, it is 
significantly upregulated in the MCF7 cell line (Figure 4.3 E) comparing with MDA-MB-231. ESR2 
mRNA expression was significantly more elevated in MDA-MB-231 cells, especially with 8h of 
starvation (Figure 4.3 F). 
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Figure 4.3 - Relative gene expression of ESR1 and ESR2 in MDA-MB-231 and MCF7 cells. (a, b, c, d) In a pulse chase 
assay, cells were cultured in medium and exposed to estradiol, C18 and C18+estradiol over 360 minutes. (a) MDA-MB-231 
cells presented higher levels of ESR1 mRNA expression in the estradiol condition in the first 30 minutes of exposure and at 90 
minutes. (b) the addition of C18 or estradiol had no effect in ESR1 expression in MCF7 cells, being higher in the control 
condition. (c) ESR2 expression was significantly upregulated in MDA-MB-231 cells while in MCF7 no differences were 
observed (d). (e) Cells were submitted to different starvation times (0h, 8h and 16h) and the basal levels of ESR1 and ESR2 
mRNA expression were analyzed.  ESR1 levels were significantly higher in MCF7 cells and ESR2 levels were greater in MDA-
MB-231. HPRT gene was used as endogenous control. Expression levels were normalized to control condition. Data are mean 
± error bars of triplicates. *p≤0.05 **p ≤0.01 ***p ≤0.001. 
 
Western blotting analysis showed that both cell lines express ER-a (codified by ESR1) and ER-
b (codified by ESR2) proteins despite being MDA-MB-231 reported as ER-. Regarding ER-a, C18 and 
estradiol increased ER-a protein levels in MDA-MB-231 (Figure 4.4 A) which is in agreement with the 
RQ-PCR results. In MCF7 no major differences were observed in both receptors corroborating with the 
mRNA levels (Figure 4.4 A and B). MCF7 cell line also exhibited higher levels of ER-a levels in 
comparison with MDA-MB-231 cells, which is also in concordance with the mRNA levels. In MDA-
MB-231, ER-b protein levels were not altered with the addition of C18 or estradiol, in fact, they were 
higher in the cells cultured in control medium which does not correspond with the RQ-PCR results 
(Figure 4.4 B). ER-b protein levels were greatest in the MCF7 cell line, which was not the case at the 
mRNA level. 
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Figure 4.4 - ER-a and ER-b levels assessed by Western blotting. Cells were cultured in control, estradiol, C18 and 
C18+estradiol conditions. Protein levels were normalized to b-actin and are relative to those obtained for cells cultured in 
control conditions. (a) MDA-MB-231 cells showed higher levels of ER-a protein in the C18 and estradiol condition; while in 
MCF7 there were no major differences between conditions. (b) ER-b protein levels decreased when cells were treated with 
estradiol and/or C18 in MDA-MB-231. In MCF7 C18+estradiol also led to a reduction in ER-b expression. 
4.2 Estradiol stimulates the binding of ER-b to FATP1/SLC27A1 promoter 
 
The involvement of estrogen signaling pathway in FATP1/SLC27A1 regulation was assessed by 
chromatin immunoprecipitation (ChIP). The relative occupancies of ER-a and ER-b on the 
FATP1/SLC27A1 promoter were measured. These transcription factors were immunoprecipitated by 
ChIP assay and then a RQ-PCR was performed to amplify the fragment of FATP1/SLC27A1 promoter 
in which Responsive Elements (ERE) sequences are located. Figure 4.5 shows that ER-b binding to 
FATP1 promoter increased upon estradiol stimulation, being statistically significant in MCF7 cells. 
Regarding ER-a, it only was observed a trend to increase in both cell lines. 
 
 
Figure 4.5 - Estradiol stimulates the binding of ER-b to promoter FATP1/SLC27A1. Cells were cultured in control and in 
estradiol conditions. The FATP1 promoter showed a significant increase of relative occupancy of ER-b after exposure to 
estradiol. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. 
 
4.3 FATP1/SLC27A1 expression is regulated by ER-b 
 
In order to evaluate the role of ER-b in FATP1/SLC27A1 regulation, cells were exposed to ERB-
041, an ER-b agonist, and to PHTPP, an ER-b antagonist. A cell viability assay was performed to 
evaluate the effect of these compounds in cells cultured in the presence or absence of estradiol with or 
without C18. Figure 4.6 shows that PHTPP, with and without C18, caused a significant increase in cell 
 16 
death in both cell lines while the other conditions did not affect cell viability. Comparing with DMSO 
condition, MDA-MB-231 cells display higher levels of cell death upon exposure to PHTPP than MCF7. 
ERB-041 did not affect cell viability in neither cell lines. 
 
 
 
 
Figure 4.6 – PHTPP affects cell viability of MDA-MB-231 and MCF7 cells. Cells were cultured in control, control DMSO, 
estradiol and/or C18 conditions, in the presence or absence of PHTPP and ERB-041.PHTPP caused a significant increase in 
cell death in both cell lines. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (#) represents the statistical 
analysis in relation to control DMSO condition. 
 
To evaluate the FA uptake upon estradiol, PHTPP and ERB-041, with and without C18, a flow 
cytometry assay was performed using Nile Red (Figure 4.7). MDA-MB-231 cells exposed to 
C18+estradiol showed a significant uptake of neutral lipids (Figure 4.7 A). When cells were exposed to 
PHTPP (ER-b antagonist), the uptake of FA was decreased, being statistically significant in the polar 
lipids in both cell lines (Figure 4.7 A and B). In MCF7 cells, ERB-041 (ER-b agonist) induces a 
significant increase in the uptake of both neutral and polar lipids (Figure 4.7 B). However, when ERB-
041 was combined with C18 the uptake decreased. C18 and estradiol separate exposure also led to a 
higher uptake of neutral lipids in MCF7 cells.  
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Figure 4.7 - MDA-MB-231 and MCF7 cells exposed to PHTPP accumulate less FA. Cells were cultured in control, control 
DMSO, estradiol and/or C18 conditions, in the presence or absence of PHTPP and ERB-041. (a) MDA-MB-231 cells displayed 
a higher uptake of neutral lipids when exposed to C18 and estradiol but when they were treated with PHTPP they accumulated 
less FA. (b) MCF7 cells showed a significant increase in the uptake when exposed to ERB-041 and when treated with the ER-
b antagonist the uptake of FA was dramatically decreased. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. 
(*) represents the statistical analysis in relation to control condition and (#) represents the statistical analysis in relation to 
control DMSO condition. 
 
Since ER-b antagonist (PHTPP) interfered with cell viability and both ER-b agonist (ERB-041) 
and antagonist (PHTPP) interfered with the uptake of FA, we then analyzed the modulation of 
FATP1/SLC27A1 expression by estradiol, PHTPP and ERB-041, in the presence and absence of C18, 
by flow cytometry. Figure 4.8 A shows that the total percentage of FATP1 positive cells was 
significantly lower when cells were treated with the ER-b antagonist (PHTPP), the same happened for 
the fluorescence intensity in both MDA-MB-231 and MCF7 cells (Figure 4.8 A and C). At the same 
time, the percentage of FATP1 positive cells in the cell membrane was significantly upregulated when 
cells were exposed to PHTPP in both cell lines (Figure 4.8 B and D).  In this assay, the ER-b agonist 
(ERB-041) did not have effects except in the membranar percentage of FATP1 positive cells in MCF7 
that was significantly enhanced ERB-041 (Figure 4.8 D). Cells exposed to C18 also had more FATP1 
positive cells in the membrane (Figure 4.8 B and D). MCF7 cells displayed a significant amount of 
membranar FATP1 positive cells when treated with C18 in combination with estradiol (Figure 4.8 D).  
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Figure 4.8 – FATP1 is upregulated in the membrane of cells treated with PHTPP. Cells were cultured in control, control 
DMSO, estradiol and/or C18 conditions, in the presence or absence of PHTPP and ERB-041. (a, c) MDA-MB-231 and MCF7 
cells exposed to PHTPP had a significant lower percentage of total FATP1 positive cells, as for fluorescence intensity of total 
FATP1, it was also significantly decreased in cells treated with PHTPP. (b) FATP1 positive cells in the membrane were 
significantly elevated after exposure to PHTPP and to C18 comparing with control conditions. (d) MCF7 cells cultured in C18 
and C18+estradiol, with ERB-041 and with PHTPP exhibited a significant increase in the percentage of FATP1 positive cells, 
however, only cells treated with PHTPP and C18 with and without estradiol displayed a higher fluorescence intensity. Results 
are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (*) represents the statistical analysis in relation to control condition 
and (#) represents the statistical analysis in relation to control DMSO condition. 
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4.4 FA and estradiol increase cell migration and proliferation 
 
As FA are metabolically crucial for the synthesis of membranes and signaling molecules, we 
investigated the effects of FA and estradiol in the migration and proliferation of breast cancer cells. For 
the migration analysis, a wound healing assay was performed over 48h. Both cell lines had a higher 
percentage of wound closure when cells were exposed to C18+estradiol condition, being this increase 
most significant after 48h of exposure (Figure 4.9 A and B). Estradiol alone also increased significantly 
migration however only in MCF7 cells (Figure 4.9 B). Proliferation was assessed by cell cycle analysis 
using flow cytometry. MDA-MB-231 cells displayed a higher percentage of cells dividing (S + G2/M 
phases) when they were exposed to C18 in combination with estradiol (Figure 4.9 C). The opposite 
happened in MCF7 cells when exposed to C18 with and without estradiol (Figure 4.9 D). 
 
 
 
Figure 4.9 - MDA-MB-231 cells exposed to C18 and estradiol migrate and proliferate more. Cells were cultured in control, 
estradiol, C18 and C18+estradiol conditions. (a), (b) C18 in combination with estradiol led to a higher migration in both cell 
lines. (c) MDA-MB-231 exposed to C18 and estradiol proliferate more. (d) MCF7 cells do not proliferate. Data are means of 
triplicates. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. 
4.5 Patients with upregulated expression of FATP1/SLC27A1 have lower overall survival and 
relapse free survival times 
 
To determine the relevance of the expression levels of the FATP1/SLC27A1 gene on the clinical 
outcome in untreated and treated breast cancer patients, a Kaplan-Meier analysis was employed. Overall 
survival (OS) was determined in grade 1 (26 patients), grade 2 (64 patients) and grade 3 (204 patients) 
breast carcinomas with high and low expression of FATP1. OS in patients with high FATP1/SLC27A1 
expression (red line) was lower than that in patients with low FATP1/SLC27A1 expression (black line) 
and that was even more apparent in more advanced stages of the disease (grade 3) although not 
0 1 3 6 9 12 24 48
0
10
20
30
30
35
40
Time (hours)
W
ou
nd
 c
lo
su
re
 (%
)
MDA-MB-231
Control 
Estradiol
C18
C18+Estradiol
*
**
* Statistical analysis in relation to the Control condition
0 1 3 6 9 12 24 48
0
10
20
30
40
Time (hours)
W
ou
nd
 c
lo
su
re
 (%
)
MCF7
Control 
Estradiol
C18
C18+Estradiol
* Statistical analysis in relation to the Control condition
**
*
**
***
MDA-MB-231 MCF7
A B
Co
ntr
ol C1
8
Es
tra
dio
l
C1
8+
Es
tra
dio
l
0
10
20
30
40
50
60
70
80
90
100
110
120
Pe
rc
en
ta
ge
 o
f c
el
ls
 (%
)
MDA-MB-231
G0-G1
S
G2-M*
Co
ntr
ol C1
8
Es
tra
dio
l
C1
8+
Es
tra
dio
l
0
10
20
30
40
50
60
70
80
90
100
110
120
Pe
rc
en
ta
ge
 o
f c
el
ls
 (%
)
MCF7
G0-G1
S
G2-M
*** ***
** ***
C D
 20 
significant (Figure 4.10 A). In Figure 4.10 B, grade 3, basal and ER- breast cancer cases (26) were 
evaluated and they are representative of the MDA-MB-231 cell line; and grade 3, luminal and ER+ 
breast cancer cases (36) were analyzed being representative of MCF7 cell line. OS in grade 3 triple 
negative breast cancer patients (basal, ER-) with high FATP1/SLC27A1 expression was significantly 
lower than that in patients with low expression. This trend was also observed for grade 3, luminal, ER+ 
patients, however with no statistical significance.  
 
 
 
Regarding relapse free survival time (RFS) analysis was assessed in grade 1 (106 patients), 
grade 2 (227 patients) and grade 3 (444 patients) breast carcinomas with high and low expression of 
FATP1/SLC27A1 (Figure 4.11 A). Patients in more advanced stages and with high expression of 
FATP1/SLC27A1 showed a lower RFS comparing with grade 1 and grade 2 patients.  
As shown in figure 4.11 B, grade 3 breast cancer patients, with a basal and ER – subtype (108), 
with high FATP1/SLC27A1 expression (red line) displayed a significantly lower RFS than patients with 
low FATP1/SLC27A1 expression (black line). A similar observation was made for grade 3, luminal, 
ER+ patients (86) but with no statistical significance. 
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Figure 4.10 – Patients with high levels of FATP1/SLC27A1 expression have a lower OS. Comparison of the overall survival 
curves of GEO patients with high levels of FATP1 (red line) and low levels of FATP1 (black line) expression using Kaplan-
Meier method. (a) Kaplan-Meier survival curves for patients with breast cancer grade 1 (n=26), grade 2 (n=64) and grade 3 
(n=204). (b) Kaplan-Meier survival curves for patients with grade 3, basal and ER – breast cancer (n=26) and grade 3, luminal 
and ER + breast cancer (n=36). 
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Figure 4.11 - Patients with high levels of FATP1/SLC27A1 expression have a lower RFS. Comparison of the relapse free 
survival curves of GEO patients with high levels of FATP1 (red line) and low levels of FATP1 (black line) expression using 
Kaplan-Meier method. (a) Kaplan-Meier RFS curves for patients with breast cancer grade 1 (n=106), grade 2 (n=227) and 
grade 3 (n=444). (b) Kaplan-Meier survival curves for patients with grade 3, basal and ER – breast cancer (n=108) and grade 
3, luminal and ER + breast cancer (n=86). 
 
4.6 Arylpiperazines interfere with FA uptake 
 
Our previous results proved that FA and estradiol are important in the regulation of 
FATP1/SLC27A1 and that this gene is upregulated in more aggressive and invasive breast carcinomas. 
Thus, the pharmacological inhibition of FATP1 might be a strategy to fight cancer. To test this 
therapeutic approach, cells were exposed to arylpiperazines, compounds that act as FATP1 inhibitors, 
interfering with the transport of FA across the cell membrane.  
The uptake of FA in cells exposed to arylpiperazines was assessed by flow cytometry using Nile 
red. Two arylpiperazines derivatives were tested, 5k and 12a in MDA-MB-231 and MCF7 cells cultured 
in control, control DMSO and estradiol with and without C18. For each derivative, two concentrations 
were used: for 5k, 0.125 and 12.5 μM, and for 12a, 12.5 and 125 μM. In figure 4.12 A, the uptake of 
neutral and polar lipids in MDA-MB-231 cells was significantly reduced by arylpiperazines when 
compared to the uptake in control cells (represented by the dot line) and in cells that were only exposed 
to C18. Both cell lines exhibited a lower uptake of neutral lipids when cells were cultured in estradiol 
and treated with 5k (4.12 A and 4.12 B). In MCF7, 5k alone did cause a lower uptake of FA but when 
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combined with C18 with and without estradiol an accumulation of lipids was observed (Figure 4.12 B). 
In terms of polar lipids, no differences were detected. 
When cells were exposed to the 12a derivative alone, the uptake of lipids was effectively 
impaired comparing with control and C18 conditions (Figure 4.12 C). However, it caused a significant 
accumulation of both neutral and polar FA when MDA-MB-231 cells were cultured in C18, in the 
presence or absence of estradiol. In figure 4.12 D, MCF7 cells exhibited high levels of uptake of lipids 
when they were exposed to C18 in the presence or absence of estradiol, even in the presence of 12a. 
Neutral lipids were not affected with the addition of arylpiperazines. Hence, the 12a derivative had a 
strong effect in the accumulation of FA. 
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Figure 4.12 - Arylpiperazines interfere with FA uptake. Cells were cultured in control, control DMSO, estradiol with and 
without C18 and exposed to arylpiperazines (5k and 12a). (a) in MDA-MB-231 cells, 5k decreased the lipid uptake while in 
MCF7 (b) an accumulation of lipids was observed. (c) 12a compound led to an increased uptake of neutral and polar FA in 
MDA-MB-231. (d) Cells cultured in C18 condition accumulated significantly more FA, even in the presence of arylpiperazines. 
Data are means of triplicates. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (*) represents the statistical 
analysis in relation to the control condition; (#) statistical analysis in relation to the control (DMSO) condition; ($) statistical 
analysis in relation to the C18 condition. The dot line defines the relative median fluorescence intensity for the control 
conditions.   
 
4.7 Arylpiperazines interfere with cell proliferation 
 
In order to understand if arylpiperazines have an effect in cell proliferation, a cell cycle assay 
was performed by flow cytometry. MDA-MB-231 cells exposed to 5k did not suffer many alterations, 
only a slight increase in dividing cells (S + G2 phases) in cells cultured in C18 and 12.5 μM of 5k and 
also in cells cultured in C18 and estradiol exposed to 12.5 μM when compared to cells exposed to 
arylpiperazines alone (Figure 4.13 A). MCF7 cells did not divide as much as the MDA-MB-231, having 
a high percentage of cells in the G0/G1 phase. When exposed to 12.5 μM of 5k cells cultured in estradiol 
and C18 exhibited a decrease in proliferating cells (Figure 4.13 B). Thus, cells in which FATP1 was 
inhibited proliferated less. In figure 4.13 C, MDA-MB-231 cells cultured in C18 and/or estradiol with 
125 μM of 12a displayed a dramatic reduction in proliferating cells. In MCF7 cells treated with 12a, no 
meaningful differences were observed (Figure 4.13 D). 
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Figure 4.13 – Arylpiperazines interfere with cell proliferation. Cells were cultured in control, control DMSO, estradiol with 
and without C18 and exposed to arylpiperazines (5k and 12a). (a) 5k (12.5 μM) led to a slight increase in proliferation in MDA-
MB-231. (b) In MCF7 cells exposed to C18 in combination with estradiol displayed a lower percentage of proliferative cells 
when treated with 12.5 μM 5k. (c) MDA-MB-231 cells exposed to 125 μM of 12a showed a significant reduction in cell 
proliferation when they were cultured in C18 and/or estradiol. (d) No differences were detected in terms of proliferation. Data 
are means of triplicates. Results are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (*) represents the statistical analysis 
in relation to the C18 condition; (#) statistical analysis in relation to the estradiol condition; ($) statistical analysis in relation 
to the C18+estradiol condition; (%) statistical analysis in relation to the 5k 12.5 μM condition; (+) statistical analysis in relation 
to the 12a 125 μM condition. 
 
4.8 Arylpiperazines effect on cell viability 
 
With the intent of analyzing the effect of arylpiperazines in cell viability, a cell death assay was 
carried out. In figure 4.14 A, MDA-MB-231 cells, the total percentage of cell death was significantly 
higher in cells cultured in C18 and C18 plus estradiol, as well as with C18 in combination with the two 
concentrations of 5k. In the MCF7 cell line, similar results were obtained but the highest percentage of 
cell death was with 12.5 μM 5k in combination with estradiol, in the presence or absence of C18 (Figure 
4.14 B). Concerning the 12a derivative, only higher concentrations (125 μM) caused increased cell death 
in MDA-MB-231 cells, which were cultured with C18 in the combination of estradiol and in separate 
(Figure 4.14 C). As for MCF7 cells, the exposition of C18 with and without 12a 125 μM also induced 
an increase in the levels of total cell death (Figure 4.14 D). Overall, MDA-MB-231 had a lower 
percentage of total cell death in comparison with MCF7. 
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Figure 4.14 - Arylpiperazines effect on cell viability. Cells were grown in control, control DMSO, estradiol with and without 
C18 and exposed to arylpiperazines (5k and 12a). (a) MDA-MB-231 cells displayed higher levels of cell death in the C18 and 
C18+estradiol conditions, as well as C18 plus arylpiperazines. (b) MCF7 showed increased cell death in cells cultured in C18 
in combination with arylpiperazines and estradiol. (c)12a effect was not very noticeable in MDA-MB-231 cells, being cell 
death most increased in cells exposed to C18+estradiol and 125 μM of 12a. (d) Cell death in MCF7 was upregulated in the 
C18, C18 plus estradiol and C18 plus 12a 125 μM conditions. Data are means of triplicates. Results are shown as mean ± SD. 
*p<0.05, **p<0.01, ***p<0.001. (*) represesents the statistical analysis in relation to the control condition; (#) statistical 
analysis in relation to the control (DMSO) condition. 
 
5. Discussion 
Cancer metabolic reprogramming has been recognized as one of the ten hallmarks by Hanahan 
and Weinberg in 2011 4. Metabolic remodeling leads to changes in biosynthetic and bioenergetic 
pathways not only in neoplastic cells but also in non-cancerous cells that share the same 
microenvironment 41. This cellular and molecular network sustains the high demanding of energy and 
biomass production which are essential for cancer initiation and progression 69. In breast and ovarian 
cancer cells it was stated that tumor microenvironment promotes tumor growth and provides a rationale 
for the development of targeted therapies that block cancer metabolism fueled by the microenvironment 
83,109. 
Cancer associated fibroblasts (CAFs) are the predominant cellular component in the tumor 
microenvironment 41,69,110, and have been shown to fuel tumor cells by producing and exporting high 
energy metabolites such as lactate, pyruvate and ketone bodies, which are used by adjacent cells 111. 
Recently, our team 50 have shown that CAFs cooperate with breast cancer cells as FA suppliers, in in 
vitro and in vivo models, through the FA transport FATP1.  Aberrant lipid metabolism has long been 
recognized as a major metabolic event during cancer development 48. However, most studies have been 
focused on de novo lipogenesis as the source for FA required for tumor cell growth, being the role of 
exogenous FA often disregarded 47,112,113. FA can also be acquired by alternate mechanisms as some 
studies have shown that cancer cells are able to internalize exogenous free FA to fuel their growth 114,115. 
The present work focuses on the uptake of exogenous FA by breast cancer cells rather than on the de 
novo FA synthesis that has been extensively investigated. Furthermore, the main objective of this thesis 
was to disclose the role of FATP1 in breast cancer cells survival and behavior and to validate its use as 
a therapeutic target. 
Our team 50 have shown that MDA-MB-231 exposed to CAFs exhibited a decreased FASN 
activity and an increased FATP1/SLC27A1 transcriptional expression suggesting that breast cancer cell 
change their metabolic feature from FA producers to FA gatherers. Hence, our first approach was to 
verify the transcriptional expression of the FATP1/SLC27A1 gene in MDA-MB-231 and MCF7 breast 
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cancer cells. We found that FATP1/SLC27A1 mRNA levels were significantly upregulated within 30 
minutes of exposure to C18+estradiol in MDA-MB-231 (Figure 4.1 A) and within 15 minutes of 
exposure to C18 in MCF7 cells (Figure 4.1 B) comparing to cells grown in control conditions. 
FATP1/SLC27A1 mRNA levels suffered a boost in expression in the first minutes of exposure but then 
decreased with time, thus, this gene seems to be able to respond very quickly to exogenous stimulus. It 
was also found that the highly aggressive and invasive MDA-MB-231 cells exhibit a significant higher 
expression of FATP1 than the poorly aggressive and non-invasive MCF7 cells (Figure 4.1 C). In such 
manner, this result suggests that enhanced FATP1/SLC27A1 expression is correlated with more 
aggressive phenotypes. Most studies have been investigating FATP1 in the context of diet induced 
obesity, insulin resistance hyperglycemia, hyperinsulinemia and hypertension 116–119. To our knowledge, 
this is the first study that investigates the role of FATP1 in breast cancer. It was found that metabolic 
genes such as SLC27 genes, including FATP1/SLC27A1, may be altered in metastatic cancer cells and 
are associated with poor prognosis 120. Moreover, an expression array analysis demonstrated that 
FATP1/SLC27A1 expression is up-regulated in human intrahepatic cholangiocarcinoma samples being 
these results validated by RQ-PCR analysis 115. 
Concerning FATP1 protein levels, we found that they were visibly higher in MDA-MB-231 cells 
exposed to C18+estradiol (Figure 4.2 A) while in MCF7 there were no repercussions with the addition 
of estradiol or FA (Figure 4.2 B). The protein expression of FATP1 was evaluated in human melanoma 
patient biopsies and it was found that 44% of patients overexpressed FATP1 specifically in the tumor 
cell compartment 121.  In vitro, we showed that in CAFs, FATP1 and FAT/CD36 were expressed in 
higher levels than in breast cancer cells, contributing for the functioning metabolic network in cancer 
microenvironment 50. On the contrary, a study showed that FATP1 alongside FAT/CD36 was 
downregulated in endometrial carcinomas as compared to healthy tissue, being accompanied by an 
upregulation of GLUT1, GLUT3 and GLUT4, suggesting that these carcinomas favor glucose 
metabolism and are less dependent of FA uptake 122.   
The discovery of the estrogen receptor (ER) provided us with a powerful, predictive and 
prognostic marker and an efficient target for the treatment of hormone-dependent breast cancer with 
antiestrogens 123. The analysis of the expression of estrogen receptors genes 1 and 2 (ESR1 and ESR2) 
by RQ-PCR (Figure 4.3) showed that MDA-MB-231 cells, an ER- cell line, exhibited a significant 
expression of ESR1 and ESR2 when cells were exposed to estradiol in combination with C18 and in 
separate. MCF7 cell line (ER+) did not respond to the stimulus as the expression levels were higher in 
the control condition (Figure 4.3 B, D). We also found that MDA-MB-231 showed a significant 
upregulated expression of ESR2 while MCF7 cells exhibited significant enhanced levels of ESR1. With 
these findings we can assume that FATP1 and ESR2 seem to be a pro-survival factor in MDA-MB-231, 
whereas ESR1 seems to be a pro-survival factor in MCF7 as its expression is higher and increases 
progressively with the starvation time. 
 Protein analysis of these receptors showed that ER-a (codified by ESR1) expression was higher 
after C18+estradiol exposure in MDA-MB-231 (Figure 4.4 A) which is in agreement with the RQ-PCR 
results. ER-b (codified by ESR2) protein levels were not altered with the addition of C18 or estradiol, 
not corroborating with the relative gene expression (Figure 4.4 B). In MCF7 no major differences were 
observed in both receptors between conditions and this cell line exhibited higher levels of ER-a levels 
in comparison with MDA-MB-231 cells, which is also in concordance with the mRNA levels (Figure 
4.4 A and B). ER-b protein levels were greatest in the MCF7 cell line, which was not the case at the 
mRNA expression. These discrepancies may be due to possible post-translational modifications such as 
phosphorylation 124, acetylation 125, ubiquitination 126, sumoylation 127 and methylation 128 that have been 
identified as event modifying ER expression and stability, subcellular localization as well as sensitivity 
to hormonal response 129. Particularly, two studies have shown that the phosphorylation of ER-
b stimulates its degradation, possibly explaining our findings relatively to the poor protein levels of ER-
b in MDA-MB-231 130. These results prove that MDA-MB-231 considered as a triple negative cell line 
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in the literature 131 expresses both estrogen receptors, especially ESR2 and that its expression is 
influenced by the addition of FA. Other studies have already shown that this cell line under certain 
culture conditions express ESR1 gene 132. 
Interestingly, a study that investigated the role of estrogen on FA release in humans showed that 
estrogen had direct effects on adipose tissue lipolysis with the finding that estrogen deficiency increased 
systemic FA release/lipolysis 133. Insulin was found to inhibit lipolysis of stored fat in the adipose tissue 
and gluconeogenesis in the liver 134 and to induce long-chain fatty acids (LCFA) uptake in adipocytes 
135. It has been shown that exposure to insulin stimulated FATP1 accompanied by an increased LCFA 
uptake in fat 96,136. In such manner, as insulin inhibits lipolysis in the adipose tissue and stimulates the 
FATP1 protein, estrogen exposure might enhance the uptake of FA through FATP1. 
The involvement of estrogen signaling pathway in FATP1/SLC27A1 regulation demonstrated 
that ER-b binding to FATP1/SLC27A1 promoter increased upon estradiol stimulation, being statistically 
significant in MCF7 cells, as for ER-a, only a trend to increase was observed in both cell lines (Figure 
4.5). Our findings suggest that ER-b seems to be relevant in the modulation of FATP1/SLC27A1 as well 
as a possible association with ER-b expression and mammary carcinogenesis. ER-α has been studied 
extensively in familial and sporadic breast cancers but there is limited information on ERβ and its 
isoforms. Studies have reported that ERβ2 expression was increased in invasive carcinomas in 
comparison with normal glands, in both ER-a-positive and ER-a-negative tumors 137 and that 
cytoplasmic ERβ2 expression correlated with shorter overall survival at 15 years 138. Moreover, an 
association of ERβ1 expression with increased cell proliferation in ER-α-negative breast cancer was 
also described 139. These evidences indicate that ER-b may have a role in the progression of breast 
carcinomas and could potentially serve as a prognostic marker. 
 With the intent of investigating further the role of ER-b in FATP1/SLC27A1 regulation, cells 
were exposed to ERB-041, an ER-b agonist 140, and to PHTPP, an ER-b antagonist 141. PHTPP, with 
and without C18, caused a significant increase in cell death in both cell lines (Figure 4.6). MDA-MB-
231 cells displayed higher levels of apoptosis upon exposure to PHTPP than MCF7. A possible 
explanation for this is that MDA-MB-231 cells are more likely to depend on ER-b in order to function 
correctly since they have lower levels of ER-α, as mentioned before. The inhibition of ER-b strongly 
induced apoptosis suggesting the crucial role of ER-b in breast cancer cells. As expected, ERB-041 did 
not affect cell viability in neither cell lines. In terms of lipid uptake, MDA-MB-231 cells exposed to 
C18+estradiol showed a significant uptake of neutral lipids (Figure 4.7 A). When cells were exposed to 
PHTPP, the uptake of FA was decreased, being statistically significant in the polar lipids in both cell 
lines (Figure 4.7 A and B). In MCF7 cells, ERB-041 with and without estradiol induced a significant 
increase in the uptake of both neutral and polar lipids (Figure 4.7 B). However, when ERB-041 was 
combined with C18 the uptake decreased, indicating that in MCF7 the agonist of ER-b might be affected 
by estradiol but not by FA. C18 and estradiol separate exposure also led to a higher uptake of neutral 
lipids in MCF7 cells. These findings indicate that ER-b is important in the uptake of FA, since its 
inhibition decreased the levels of FA. We can also observe that C18 in combination with estradiol is 
associated with an enhanced uptake of FA that might be transported by FATP1.  
The total percentage of FATP1 positive cells was significantly lower when cells were treated 
with the ER-b antagonist (PHTPP) in both MDA-MB-231 and MCF7 cells (Figure 4.8 A and C). At the 
same time, the percentage of FATP1 positive cells in the cell membrane was significantly higher when 
cells were exposed to PHTPP in both cell lines (Figure 4.8 B and D). These findings indicate that PHTPP 
is translocated to the membrane. In this assay, the ER-b agonist (ERB-041) did not have strong effects 
except in the membranar percentage of FATP1 positive cells in MCF7 that was significantly enhanced 
by ERB-041 (Figure 4.8 D). Cells exposed to C18 also showed more FATP1 positive cells in the 
membrane in both cell lines (Figure 4.8 B and D), which is in agreement with the higher levels of FA 
uptake observed in these conditions in figure 4.7.  MCF7 cells displayed a significant amount of 
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membranar FATP1 positive cells when treated with C18 in combination with estradiol (Figure 4.8 D). 
These results demonstrate that a higher uptake of FA corresponds to an increased percentage of FATP1 
positive cells, therefore, FA are likely to be transported by FATP1 across the cell membrane. When ER-
b is impaired (after PHTPP treatment) it triggers apoptosis in breast cancer cells (Figure 4.6) and leads 
to a decreased uptake of FA (Figure 4.7) and to compensate, the percentage of FATP1 membrane 
positive cells increased significantly. 
Cancer is essentially a mitogenic disorder, which requires cellular building blocks, such as 
nucleic acids, proteins, and lipids 45. Wound healing results revealed an enhanced migration when cells 
were exposed to C18+estradiol (Figure 4.9 A and B). Estradiol alone also increased significantly 
migration however only in MCF7 cells (Figure 4.9 B). Moreover, MDA-MB-231 cells displayed a 
higher percentage of proliferating cells when they were exposed to C18 in combination with estradiol 
(Figure 4.9 C). The opposite happened in MCF7 cells when exposed to C18 with and without estradiol 
(Figure 4.9 D). All in all, these findings indicate that FA and estradiol induce migration and cell 
proliferation in MDA-MB-231. It was reported that adipocyte-derived FA enhanced breast cancer cells 
proliferation and migration 142, and that FA uptake into pancreatic cancer cells increased the migration 
and invasiveness 143 corroborating our results. Another study described that human LDL stimulated 
proliferation of ER- MDA-MB-231 cells, but had little effect on proliferation of ER+ MCF-7 cells 144 
which is in agreement with our findings (Figure 4.9 C and D).  
Kaplan-Meier curves revealed that patients with upregulated expression of FATP1/SLC27A1 
showed lower overall survival (OS) and relapse free survival (RFS) in comparison with patients with 
low expression of FATP1/SLC27A1 and that was even more apparent in more advanced stages of the 
disease (grade 3) (Figure 4.10 and 4.11). Moreover, OS in grade 3 triple negative breast cancer patients 
(basal, ER-) with high FATP1/SLC27A1 expression was dramatically lower than OS in grade 3, luminal, 
ER+ patients. These findings reveal that the FATP1/SLC27A1 gene is undoubtedly relevant on the 
clinical outcome of breast cancer as more aggressive and invasive carcinomas (basal, ER-) exhibit a 
significantly upregulated expression of FATP1/SLC27A1. In that way, FATP1 could be considered as a 
marker for disease outcome.  
Exploiting the features of cancer metabolism for cancer detection and treatment is a very 
promising strategy in cancer therapeutics, diagnosis and prevention 145. In many tumors, lipids are 
provided via de novo lipogenesis, showing an upregulation of FASN  particularly in melanoma, breast 
and prostate cancer 57,146,147. Inhibition of FASN by either small molecules (C75, orlistat) or small 
interfering RNA can efficiently suppress tumor cell growth in vitro and xenograft models 148–150. 
However, most FASN inhibitors show several adverse and side effects 60 and our group has found that 
MDA-MB-231 exposed to CAFs exhibited a decreased FASN activity and an increased FATP1 50. 
Accordingly, the pharmacological inhibition of FATP1 might be a strategy to fight cancer. Breast cancer 
cells were exposed to arylpiperazines (5k and 12a) that act as FATP1 inhibitors, interfering with the 
transport of FA across the cell membrane. We found that the uptake of neutral and polar lipids in MDA-
MB-231 cells was significantly reduced by arylpiperazines (5k) when compared to the uptake in control 
cells and in cells that were only exposed to C18 (Figure 4.12 A). In MCF7, 5k alone did cause a lower 
uptake of FA but when combined with C18 with and without estradiol an accumulation of lipids was 
observed (Figure 4.12 B). When cells were exposed to the 12a derivative alone, the uptake of lipids was 
effectively impaired (Figure 4.12 C). However, it caused a significant accumulation of both neutral and 
polar FA when cells were cultured in C18, in the presence or absence of estradiol in both cell lines 
(Figure 4.12 C and D). Hence, the 12a derivative had a strong effect in the accumulation of FA while 
5k significantly reduced the uptake of FA but only in MDA-MB-231. Therefore, the 5k compound might 
be a good inhibitor of FA uptake but only in cancer cells that express high levels of FATP1. However, 
more studies should be done to optimize 5k and to validate this finding. Understanding how free FA 
move across the cell membrane has proven to be a challenging biophysical and biochemical problem, 
which after 30 years of research is still only poorly understood and remains controversial 151. FATP1 
has been postulated to mediate bi-directional transport of LCFA across the plasma membrane of 
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adipocytes 152. Hence, the 12a compound might be inhibiting the transport of FA to the extracellular 
milieu causing an accumulation of FA in the cell. Another possible explanation is that other FA 
transporters such as FATP4 or CD36 which are highly expressed in adipose tissue 153 might be 
upregulated since FATP1 function is impaired.  
When exposed to 5k MCF7 cells cultured in estradiol and C18 exhibited a decrease in 
proliferating cells (Figure 4.13 B) and MDA-MB-231 cells cultured in C18 and/or estradiol with 12a 
displayed, as well, a dramatic reduction in proliferating cells (Figure 4.13 C). Therefore, cells in which 
FATP1 was inhibited proliferated less. Regarding cell viability, in MDA-MB-231 cells, the percentage 
of cell death was significantly higher in cells cultured in C18 and C18 plus estradiol, as well as with 
C18 in combination with arylpiperazines (5k). In the MCF7 cell line, similar results were obtained 
(Figure 4.14 B). Concerning the 12a derivative, only higher concentrations caused increased cell death 
in MDA-MB-231 cells, which were cultured with C18 in the combination of estradiol and in separate 
(Figure 4.14 C). As for MCF7 cells, the exposure to C18 with and without 12a 125 μM also induced an 
increase in the levels of total cell death (Figure 4.14 D). Overall, MDA-MB-231 had a lower percentage 
of total cell death in comparison with MCF7. Apart from adipocytes, most cells have a limited capacity 
for lipid storage and when this capacity is exceeded, as in the case of FA overload, cell death may result 
from a process called lipotoxicity 67. This evidence might explain the higher cell death observed when 
only C18 was added. Despite the fact that the tested concentrations of arylpiperazines did not 
significantly induce apoptosis in these breast cancer cells, they could be used as an adjuvant therapy to 
sensitize breast cancer cells in combination with chemotherapy in order to kill cancer cells more 
efficiently.  
In the literature, it was reported using a mouse model that the expression of FASN was 
frequently down regulated in intrahepatic cholangiocarcinoma (ICC) and a robust uptake of exogenous 
FA by ICC cells was found 115. The same authors referred that in a pilot study, they found that 
suppression of SLC27A1 by specific small interfering RNA decreased the in vitro growth of HUCCT1 
and HuH28 ICC cell lines. In prostate cancer, increased FA uptake by cancer cells enhanced cell 
invasiveness in vitro and both primary tumor growth and distant metastasis in vivo 143. Another very 
recent study demonstrated that adipocyte-derived lipids were taken up by FATP1 that are aberrantly 
expressed in melanoma 121. They stained a series of freshly isolated tumors from both primary and 
metastatic sites (subcutaneous, lymph nodes, and brain) for both FATP1 and lipids using Oil Red O, 
which revealed a strong positive correlation for FATP1 versus Oil Red O staining meaning that FATP1 
showed the ability to mediate the uptake of LCFA. Inhibition of FATPs with lipofermata (FATP2 
inhibitor) decreased melanoma lipid uptake, invasion, and growth. These findings are in agreement with 
our results despite the use of a FATP2 inhibitor instead of arylpiperazines.  
It has been hypothesized that a high-fat diet is associated with the development of 
postmenopausal breast cancer 154. Our study also raises this question: do the dietary factors and obesity 
play a role in the progression of breast cancer? As FATP1 is an insulin sensitive transporter 96, it is in 
agreement with the use of anti-diabetic drugs in cancer treatment which is described by some studies 
155. Therefore, the use of arylpiperazines could eventually help with insulin resistance, diabetes or 
obesity.  
In conclusion, in this thesis we unraveled the crucial role of ER-b in FATP1/SLC27A1 
regulation and modulation in the uptake of FA. Estradiol and an increased uptake of FA fuel migration 
and cell proliferation in vitro. Our in vitro findings are validated by patients’ data showing a higher 
expression of FATP1/SLC27A1 in more aggressive and invasive breast carcinomas which promotes the 
progression of the disease. The inhibition of FATP1 with arylpiperazines interfered with the uptake of 
FA and cell proliferation, consistent with the importance of FATP1 as a putative therapeutic target in 
breast cancer.  
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Figure 5.1 – Stimulation of estrogen receptor b (ER-b) by estradiol (E2) contributes for FATP1/SLC27A1 expression, 
cell survival, proliferation and migration of BCCs (breast cancer cells). FATP1 is also a pro-survival element, mediating 
the transport of fatty acids (FA), which are essential for BCCs (a). BCCs exposed to PHTPP (ER-b antagonist) show a 
decreased cell viability and lower uptake of FA suggesting that ER-b controls FATP1/SLC27A1 expression (b). The inhibition 
of FATP1 with arylpiperazines interferes with cell viability, proliferation and with the uptake of FA, indicating that FATP1 is 
a putative therapeutic target in breast cancer (c). 
 
5.1 Future perspectives  
 
As future perspectives, to understand the role of FATP1 in breast cancer biology and to eventually 
validate FATP1 as a marker for breast cancer prognosis and putative therapeutic target, it would be 
important to: 
 
- perform a stable knockdown/knockout of FATP1/SLC27A1; 
- perform a wound healing and proliferation assay with the ER-b antagonists (PHTPP) and agonists 
(ERB-041) and ER-a antagonists (fulvestrant and MPP); 
- evaluate the percentage of FATP1 positive cells in the cell and in the membrane, lipid uptake and cell 
viability with ER-a antagonists (fulvestrant and MPP); 
- validate of our results with a normal immortalized breast cell line (MCF10A); 
- test the effect of other concentrations of arylpiperazines; 
- test the effect of arylpiperazines in the cell cycle to assess the biological processes; 
- perform a viability assay with arylpiperazines in combination with chemotherapeutic agents, and 
- evaluate FATP1 expression in breast cancer sections by immunohistochemistry. 
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Appendices  
 
Solutions prepared for the experimental work: 
 
10X PBS (pH 7.4-7.6)  
For 1L:  
80g NaCl (1.37M) (106404, Merck)  
2g KH2PO4 (14.7mM) (104873, Merck)  
11.1g Na2HPO4 (78.1mM) (S-0876, Sigma)  
2g KCl (26.8mM) (104936, Merck)  
ddH2O to 1L  
 
50 μg/mL Propidium Iodide (PI) solution – Cell cycle assay  
For 50 mL:  
1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in 1X PBS)  
49 mL 1X PBS  
0.1 mg/mL RNase A (Easy spin kit, Citomed)  
0.05% Triton X-100 (T8787, Sigma)  
 
50 μg/mL Propidium Iodide (PI) solution – Apoptosis assay  
For 50 mL:  
1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in 1X PBS)  
49 mL 1X PBS  
 
Annexin binding buffer 1X  
0.01 M Hepes (pH 7.4) (391333, Millipore)  
0.14 M NaCl (106404, Merck)  
2.5 mM CaCl2 (449709, Sigma)  
 
RIPA buffer  
For 10 mL:  
20 mM Tris-HCl pH 7.5  
150 mM NaCl (106404, Merck)  
5mM KCl (104936, Merck)  
5mM MgCl2 (M-8266, Sigma)  
1% Triton X-100 (T8787, Sigma)  
ddH2O to 10 mL  
1 Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablet 
(11836170001, Roche)  
1 mM Orthovanadate (Na3VO4)  
1 mM Sodium fluoride (NaF) (201154, Sigma)  
 
 
Transfer buffer  
For 5L:  
75g glycine (US16407, USB)  
15g Trizma-base (T-8524, Sigma)  
ddH2O to 4L  
1L Metanol (107018, Merck)  
5mL 10% SDS (V6551, Promega)  
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5X SDS gel loading buffer (Sambrook & Russel, 2001)  
250 mM Tris HCl (pH 6.8) (0.5M 161-0799, Bio-rad)  
10% SDS (V6551, Promega)  
0.5% bromophenol blue  
 
PBS 0.1% (v/v) Tween 20  
For 1L:  
1mL Tween 20 (20605, USB)  
1X PBS to 1L  
 
5% (w/v) skim milk in PBS 0.1% (v/v) Tween 20  
5g skim milk (Molico, Nestlé)  
100 mL PBS 0.1% (v/v) Tween 20  
 
3% (w/v) skim milk in PBS 0.1% (v/v) Tween 20  
3g skim milk (Molico, Nestlé)  
100 mL PBS 0.1% (v/v) Tween 20  
 
PBS 0.1% (w/v) BSA  
0.1g BSA (A9647, Sigma)  
100 mL 1X PBS  
 
CHIP lysis buffer  
50 mM Tris-HCL (pH 8.0) 
10 mM EDT 
1% SDS  
1 Complete, Mini, EDTA-free Protease Inhibitor Cocktail  
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Supplementary Table 1 – Primers sequences used during the experimental work 
 
 
Primer Forward (5´-3´)  Reverse (5´-3’)  
FATP1 CAACATGGACGGCAAGGTC CAGCAGCTCCATTGTGTCCTC 
ESR1 GCCAGGCTTTGTGGATTTGAC GGAGCAAACAGTAGCTTCCC 
ESR2 GATCTTGTTCTGGACAGGGATG GGAATTGAGCAGGATCATGGC 
HPRT TGACACTGGCAAAACAATGCA GGTCGTTTTTCACCAGCAAGCT 
FATP1 promoter GACTGTTGTAAGATTGGCAGGG CTGGGATTGGTCAACTCCTC 
 
 
 
